{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:51:13Z","timestamp":1770965473910,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.clinthera.2008.09.002","type":"journal-article","created":{"date-parts":[[2008,10,6]],"date-time":"2008-10-06T08:24:48Z","timestamp":1223281488000},"page":"1639-1650","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study"],"prefix":"10.1016","volume":"30","author":[{"given":"Anna","family":"Solans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki","family":"Izquierdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Donado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Antonijoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel-l\u00ed","family":"Carb\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Merlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Barbanoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.09.002_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(24)36413-4","article-title":"Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)","volume":"280","author":"Merlos","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2008.09.002_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00003495-200767030-00008","article-title":"Rupatadine: A review of its use in the management of allergic disorders","volume":"67","author":"Keam","year":"2007","journal-title":"Drugs"},{"issue":"Suppl 73","key":"10.1016\/j.clinthera.2008.09.002_bib3","first-page":"245","article-title":"Rupatadine in allergic rhinitis: Pooled analysis of efficacy data","volume":"57","author":"P\u00e9rez","year":"2002","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2008.09.002_bib4","first-page":"22","article-title":"Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: A randomised, double-blind parallel study","volume":"15","author":"Mart\u00ednez-C\u00f3cera","year":"2005","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2008.09.002_bib5","first-page":"34","article-title":"A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis","volume":"14","author":"Saint-Martin","year":"2004","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clinthera.2008.09.002_bib6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1398-9995.2004.00576.x","article-title":"Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: A comparison study","volume":"59","author":"Guada\u0144o","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2008.09.002_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000080959","article-title":"Central and peripheral evaluation of rupatadine, a new antihistamine\/platelet-activating factor antagonist, at different doses in healthy volunteers","volume":"50","author":"Barbanoj","year":"2004","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.clinthera.2008.09.002_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1517\/14656566.7.6.639","article-title":"Drug interactions during therapy with three major groups of antimicrobial agents","volume":"7","author":"Shakeri-Nejad","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2008.09.002_bib9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2008.09.002_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2125.2000.00261.x","article-title":"Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycin","volume":"50","author":"Westphal","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2008.09.002_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2008.09.002_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0149-2918(01)80049-7","article-title":"Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebocontrolled, parallel-group study","volume":"23","author":"Gupta","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2008.09.002_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5414\/CPP38161","article-title":"P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans","volume":"38","author":"Schwarz","year":"2000","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2008.09.002_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/bmj.321.7266.913","article-title":"Doctors revise declaration of Helsinki","volume":"321","author":"Christie","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2008.09.002_bib15","unstructured":"European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Step 5. Note for guidance on Good Clinical Practice (CPMP\/ICH\/135\/95). Geneva, Switzerland: WHO; 2002. http:\/\/www.emea.eu.int. Accessed April 11, 2007."},{"key":"10.1016\/j.clinthera.2008.09.002_bib16","unstructured":"Guidance for Industry. Bioanalytical Method Validation US Dept of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), May 2001."},{"key":"10.1016\/j.clinthera.2008.09.002_bib17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation\u2014A revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2008.09.002_bib18","unstructured":"Guidance for Industry. Statistical approaches to establishing bioequivalence. US Dept of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2001."},{"key":"10.1016\/j.clinthera.2008.09.002_bib19","unstructured":"Zithromax (azithromycin) clinical pharmacology. Pharmacokinetics [Rxlist Web site]. http:\/\/www.rxlist.com\/cgi\/generic\/azith_cp.htm. Accessed May 11, 2005."},{"key":"10.1016\/j.clinthera.2008.09.002_bib20","first-page":"105","article-title":"Macrolide antibacterials. Drug interactions of clinical significance","volume":"13","author":"von Rosensteil","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2008.09.002_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.48.3.809-814.2004","article-title":"Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin","volume":"48","author":"Sugie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.09.002_bib22","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1046\/j.0306-5251.2001.00031.x","article-title":"The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers","volume":"53","author":"Muirhead","year":"2002","journal-title":"Br J Clin Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.09.002_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2125.2003.01996.x","article-title":"No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2008.09.002_bib24","unstructured":"Clarinex (desloratadine). Summary product characteristics [Web site]. http:\/\/www.spfiles.com\/piclarinex.pdf. Accessed April 7, 2008."},{"key":"10.1016\/j.clinthera.2008.09.002_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clpt.2003.11.033","article-title":"Prevalence of the slow metabolizer (SM) phenotype and single dose pharmacokinetics (PK) of desloratadine (DCL) in a population of healthy adults","volume":"75","author":"Frick","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.09.002_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14740338.5.2.211","article-title":"Adult and paediatric poor metabolisers of desloratadine: An assessment of pharmacokinetics and safety","volume":"5","author":"Prenner","year":"2006","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808002956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808002956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:11:47Z","timestamp":1738408307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808002956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0149291808002956"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.09.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}